Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

The subtypes, and why naming them matters

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

AIDS-related lymphoma is not one disease, and treating it as one is the most common error in material written about it.

The subtypes differ so much that the CD4 count at diagnosis often predicts which one it will be, before anyone looks down a microscope.

Illustration of a stained tissue section showing dense sheets of large dark purple lymphoma cells filling the field, with pale strands of supporting tissue between them.
Dense sheets of large abnormal B-cells, filling the tissue and leaving none of the normal architecture of a lymph node. Pathologists look at the size and shape of these cells, test which surface markers they carry, and check for specific chromosome rearrangements. Those three answers decide the subtype, and the subtype decides the treatment.Illustration created for OwieClear. A drawing, not a photograph of a real sample.

Related pages: AIDS-related lymphoma

The bottom line

What we know
What is still open
  • Why particular subtypes occur at particular CD4 ranges.
  • How best to treat the rarer subtypes, where evidence is limited.

The story, step by step

  1. 1. DLBCL ()
  2. 2. Burkitt ()
  3. 3. Primary CNS lymphoma ()
  4. 4. Plasmablastic and primary effusion ()
  5. 5. Hodgkin lymphoma ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

The most common one

Review of many studies

What happens

Diffuse large B-cell lymphoma accounts for roughly half of AIDS-related lymphomas.

What the research shows

  • It occurs across the whole range of CD4 counts, including in people with well-controlled HIV.
  • EBV is found in a substantial minority of cases, more often in the immunoblastic variant seen at lower CD4 counts.
  • It usually presents at an advanced stage, with disease in several areas and often outside the lymph nodes: the gut, the liver, the bone marrow.
  • Treatment is chemotherapy combined with rituximab, an antibody against the CD20 molecule on the surface of the cells.
  • With HIV controlled and modern regimens, cure rates approach those seen in people without HIV.

Why it matters

This is the subtype most people with this diagnosis will have, and it is the one with the best-established treatment and the best outcomes.

What's still uncertain

  • Testing for MYC, BCL2 and BCL6 rearrangements is needed because double-hit disease is treated differently.

Read more

Next: Burkitt

Part 2 of 5

The fastest-growing cancer known

Review of many studies

What happens

Burkitt lymphoma accounts for roughly a fifth to a third of cases and behaves unlike anything else.

What the research shows

  • It tends to occur in people with relatively preserved CD4 counts, often above 200.
  • It is defined by a translocation moving MYC next to an antibody gene, switching cell growth permanently on.
  • Under the microscope it has a characteristic starry-sky appearance, from scavenging cells clearing the debris of cells dying as fast as they are made.
  • Essentially every cell is dividing. Tumour volume can double in roughly a day, which makes it a medical emergency rather than an outpatient problem.
  • That speed creates a specific danger: tumour lysis syndrome, where cells destroyed by treatment release their contents fast enough to damage the kidneys and the heart.

Why it matters

Burkitt lymphoma is one of the few cancers where treatment must start within days, and where the first danger is the treatment working too well.

What's still uncertain

  • Despite its aggressiveness it is highly curable with appropriate intensive treatment.

Read more

Next: Primary CNS lymphoma

Part 3 of 5

Confined to the brain

Review of many studies

What happens

This subtype occurs at the lowest CD4 counts of all and is almost entirely a disease of advanced immunosuppression.

What the research shows

  • It typically occurs with CD4 counts below 50, and in this setting EBV is found in essentially 100 percent of cases.
  • It stays within the brain, spinal cord, the covering membranes and the eyes, rather than involving lymph nodes.
  • It presents with confusion, personality change, headache, seizures, or weakness on one side.
  • On MRI it produces enhancing lesions that can closely resemble cerebral toxoplasmosis, which is far more common and completely different to treat.
  • Treatment is based on high-dose methotrexate, given with antiretroviral therapy, because restoring immune control of EBV is part of the treatment.

Why it matters

The distinction from toxoplasmosis is the most consequential diagnostic decision in HIV neurology, and it has its own page.

What's still uncertain

  • Whole-brain radiotherapy is now generally avoided because of long-term cognitive effects.

Read more

Next: Plasmablastic and primary effusion

Part 4 of 5

The rare, difficult ones

Review of many studies

What happens

Two uncommon subtypes behave very differently from the rest and are worth recognizing.

What the research shows

  • Plasmablastic lymphoma occurs at low CD4 counts, is usually EBV-positive, and has a characteristic preference for the mouth and jaw before the gut.
  • Its cells have lost the usual B-cell surface markers and look like plasma cells instead, which means rituximab does not work, because there is no CD20 for it to bind.
  • Primary effusion lymphoma is driven by KSHV in essentially every case and usually EBV-positive as well.
  • It presents as fluid collecting in the chest, around the heart or in the abdomen, with no solid tumour mass, which makes it easy to mistake for infection or heart failure.
  • Both are treated with intensive chemotherapy, sometimes with bortezomib or stem cell transplant, and both remain difficult.

Why it matters

An oral or jaw mass in someone with HIV is the classic presentation of plasmablastic lymphoma, and it is frequently assumed to be dental at first.

What's still uncertain

  • Evidence for treating both of these comes from small series rather than randomized trials.

Read more

Next: Hodgkin lymphoma

Part 5 of 5

Not AIDS-defining, and far more common

Review of many studies

What happens

Hodgkin lymphoma sits in an odd category and is often left out of discussions of this topic.

What the research shows

  • It is not classified as an AIDS-defining illness, yet it occurs many times more often in people with HIV than in the general population.
  • Unusually, its incidence did not fall after effective HIV treatment arrived, and in some analyses it rose, possibly because partial immune recovery provides the inflammatory environment these tumours depend on.
  • In people with HIV it is more often of the mixed cellularity or lymphocyte-depleted type, and almost always EBV-positive.
  • It presents at a more advanced stage, more often with bone marrow involvement and B symptoms, than in people without HIV.
  • Treatment is standard Hodgkin chemotherapy given alongside antiretroviral therapy, and outcomes are now good.

Why it matters

Hodgkin lymphoma behaving differently from every other subtype in the ART era is one of the genuinely surprising findings in this field.

What's still uncertain

  • Why its incidence did not fall with treatment is not settled.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.